CREBBP and non-small cell lung carcinoma: The CBP/p300 HAT inhibitor C646 sensitizes non-small cell lung cancer cells to radiotherapy by abrogating checkpoint maintenance and augmenting radiotherapy-induced mitotic catastrophe 105.